WO2022010436A1 - A formulation comprising vildagliptin and at least one pharmaceutically acceptable excipient - Google Patents

A formulation comprising vildagliptin and at least one pharmaceutically acceptable excipient Download PDF

Info

Publication number
WO2022010436A1
WO2022010436A1 PCT/TR2021/050444 TR2021050444W WO2022010436A1 WO 2022010436 A1 WO2022010436 A1 WO 2022010436A1 TR 2021050444 W TR2021050444 W TR 2021050444W WO 2022010436 A1 WO2022010436 A1 WO 2022010436A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
vildagliptin
tablet formulation
formulation according
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2021/050444
Other languages
French (fr)
Inventor
Vildan TOMBAYOGLU
Arzu PALANTOKEN
Fatih Sunel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority to EP21837553.3A priority Critical patent/EP4175632A4/en
Publication of WO2022010436A1 publication Critical patent/WO2022010436A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a tablet formulation comprising vildagliptin and at least one pharmaceutically acceptable excipient, so the formulation provides the desired stability and pharmacotechnical properties.
  • the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the formulation comprising vildagliptin.
  • Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors.
  • Type 1 and Type 2 There are two main types of diabetes; Type 1 and Type 2:
  • Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
  • Type 2 diabetes the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
  • Vildagliptin is a dipeptidyl dipeptidase-IV (DPP-IV) inhibitor developed for use in the treatment of type 2 diabetes (non-insulin dependent diabetes).
  • DPP-IV dipeptidyl dipeptidase-IV
  • vildagliptin inhibits the degradation of the dipeptidyl dipeptidase-IV enzyme, thereby inhibiting the effects of incretin hormones, glucagon-like peptide-1 (GLP-1), and of glucose-dependent insulinotropic peptide (GIP).
  • GLP-1 glucagon-like peptide-1
  • GIP glucose-dependent insulinotropic peptide
  • the chemical designation of vildagliptin is (S)- ⁇ [(3-hydroxyadamantan-1- yl)amino]acetyl ⁇ pyrrolidine-2-carbonitril, with the chemical structure illustrated below in Formula I.
  • Vildagliptin is an active agent that is highly-susceptible to air and humidity conditions. When vildagliptin is initially exposed to air and humidity, it degrades structurally and develops chemical behavioral changes. As a result of this, two main problems emerge. The first problem is that the stability of the products developed is not at a desired level and the shelf life thereof is shortened. Secondly, vildagliptin is reactive against the excipients employed in developing formulations. This fact causes impurities and unwanted components to be included into the formulation.
  • a further problem encountered while developing formulations comprising vildagliptin is flowability. Problems encountered in the flowability of vildagliptin make its production difficult.
  • the patent application WOOO/34241 discloses vildagliptin or an acid addition salt thereof, as well as their use in diabetes mellitus and obesity.
  • the patent application W02006/078593 claims a direct-compression formulation of a DPP-IV inhibitor compound, and preferably of vildagliptin or an acid addition salt thereof.
  • the patent application W02006/135723 discloses a formulation, comprising vildagliptin as an active agent, as well as hydroxypropyl methylcellulose, microcrystalline cellulose, and magnesium stearate.
  • the main object of the present invention is to provide a formulation comprising vildagliptin having pharmacotechnical properties such as flowability, compressibility and homogeneity.
  • Another object of the present invention is to provide a formulation comprising vildagliptin having desired stability without side reactions and chemical impurities.
  • a tablet formulation comprises;
  • colloidal silicone dioxide in the formulation wherein tablet is free of coating.
  • colloidal silicone dioxide is used, so while the formulation comprising vildagliptin is provided pharmacotechnical properties, especially, flowability. Also, certain amounts of excipients are used so while the stable formulation is provided without side reactions and chemical impurities.
  • the formulation has been developed by using standard techniques which is a simple and cost-effective method.
  • vildagliptin crystal form “Form A” is used in the tablet formulation.
  • the term “vildagliptin” refers to vildagliptin form A in the present invention.
  • Suitable fillers are selected from group comprising microcrystalline cellulose, lactose anhydrous, dicalcium phosphate dihydrate, ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, tragacanth, trehalose, polysorbate 80, xylitol or mixtures thereof.
  • the amount of the fillers is between 65.0% and 80.0% by weight of the total formulation.
  • the filler is microcrystalline cellulose, lactose anhydrous, dicalcium phosphate dihydrate or mixtures thereof.
  • Suitable disintegrants are selected from group comprising croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, sodium alginate or mixtures thereof. According to one embodiment of the present invention, preferably the amount of the disintegrants is between 3.0% and 7.0% by weight of the total formulation.
  • the disintegrants is croscarmellose sodium.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, dextrin, polymethacrylates, pregelatinized starch, sodium alginate, synthetic resins, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, sodium alginate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, polysaccharides, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the binder is polyvinylpyrrolidone.
  • Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium chlorate, magnesium lauryl sulfate, sodium acetate, sodium benzoate, polyethylene glycol, sodium lauryl sulphate or mixtures thereof.
  • the lubricant is magnesium stearate.
  • the tablet formulation further comprising at least one antioxidant.
  • Suitable antioxidants are selected from the group comprising alpha tocopherol (Vitamin E), quercetine ascorbyl palmitate, ascorbic asit, tartaric asit, cysteine, Lecithin, acetic acid, alpha lipoic acid, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), erythorbic acid, monothioglycerol, potassium metabisulfite, propyl gallate, sodium ascorbate, sodium metabisulfite, sodium sulfite, citric acid, thymol or mixtures thereof.
  • antioxidants are selected from quercetine, alpha tocopherol(vitamin E), butylhydroxyanisole or butylhydroxytoluene or mixtures thereof.
  • the amount of antioxidants is between 0.1% and 3.0% by weight of the total formulation.
  • particle size distribution means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis) .
  • d(0.1) means, the size at which 10% by volume of the particles are finer
  • d(0.5) means the size at which 50% by volume of the particles are finer
  • d (0.9) means the size at which %90 by volume of the particles are finer.
  • vildagliptin has a d (0.1) particle size between 1 pm to 60 pm, preferably 4 pm to 50 pm, between 4 pm to 40 pm, between 4 pm to 30 pm, between 4 pm to 20 pm, between 6 pm to 18 pm.
  • vildagliptin has a d (0.5) particle size between 70 pm to 130 pm, preferably 75 pm to 125 pm, between 80 pm to 120 pm, between 85 pm to 115 pm.
  • vildagliptin has a d (0.9) particle size between 270 pm to 450 pm, preferably 280 pm to 440 pm, between 290 pm to 430 pm, between 300 pm to 420 pm, between 300 pm to 410 pm, between 300 pm to 400 pm.
  • vildagliptin has a d (0.1) particle size between 1 pm to 60 pm, a d (0.5) particle size between 70 pm to 130 pm, a d (0.9) particle size between 270 pm to 450 pm.
  • This invention provides surprisingly better solubility and also helps to ensure desired pharmacotechnical properties.
  • the tablet formulation of the present invention may be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, dry granulation, slugging, spray drying.
  • the sachet formulation is obtained by using a dry granulation method therefore, a simple and low-cost production method was employed.
  • Example 1 The tablet formulation comprising vildagliptin
  • Example 2 The tablet formulation comprising vildagliptin
  • a process for example 1 or 2 a) Mixing vildagliptin, colloidal silicone dioxide, a part of lactose anhydrous, a part of microcrystalline cellulose, b) Adding croscarmellose sodium, the remained of lactose anhydrous, the remained of microcrystalline cellulose, polyvinylpyrrolidone and then mixing, c) Compacting the mixture with a compactor and then sieving, d) Adding magnesium stearate and mixing, e) Pressing the mixture to form a tablet.
  • Example 3 The tablet formulation comprising vildagliptin
  • Example 4 The tablet formulation comprising vildagliptin
  • a process for example 3 or 4 a) Mixing vildagliptin, colloidal silicone dioxide, a part of lactose anhydrous, a part of dicalcium phosphate dihydrate and at least one antioxidant, b) Adding croscarmellose sodium, the remained of lactose anhydrous, the remained of dicalcium phosphate dihydrate, polyvinylpyrrolidone and then mixing, c) Compacting the mixture with a compactor and then sieving, d) Adding magnesium stearate and mixing, e) Pressing the mixture to form a tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a tablet formulation comprising vildagliptin and at least one pharmaceutically acceptable excipient, so the formulation provides the desired stability and pharmacotechnical properties. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the formulation comprising vildagliptin.

Description

A FORMULATION COMPRISING VILDAGLIPTIN AND AT LEAST ONE PHARMACEUTICALLY ACCEPTABLE EXCIPIENT
Field of Invention
The present invention relates to a tablet formulation comprising vildagliptin and at least one pharmaceutically acceptable excipient, so the formulation provides the desired stability and pharmacotechnical properties. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the formulation comprising vildagliptin.
Background of the Invention
Diabetes mellitus is a group of disorders of carbohydrate metabolism in which the action of insulin is diminished or absent through altered secretion, decreased insulin activity or a combination of both factors. There are two main types of diabetes; Type 1 and Type 2:
Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged. In Type 1 diabetes, the pancreas makes little or no insulin, so sugar cannot get into the body's cells for use as energy. People with Type 1 diabetes must use insulin injections to control their blood glucose.
In Type 2 diabetes, the pancreas makes insulin, but it either doesn't produce enough, or the insulin does not work properly. This diabetes occurs most often in people who are over 40 years old and overweight. Type 2 diabetes may sometimes be controlled with a combination of diet, weight management, and exercise. However, treatment also may include oral glucose-lowering medications or insulin injections.
Vildagliptin is a dipeptidyl dipeptidase-IV (DPP-IV) inhibitor developed for use in the treatment of type 2 diabetes (non-insulin dependent diabetes). Vildagliptin inhibits the degradation of the dipeptidyl dipeptidase-IV enzyme, thereby inhibiting the effects of incretin hormones, glucagon-like peptide-1 (GLP-1), and of glucose-dependent insulinotropic peptide (GIP). The chemical designation of vildagliptin is (S)-{[(3-hydroxyadamantan-1- yl)amino]acetyl}pyrrolidine-2-carbonitril, with the chemical structure illustrated below in Formula I. Formula I
Vildagliptin is an active agent that is highly-susceptible to air and humidity conditions. When vildagliptin is initially exposed to air and humidity, it degrades structurally and develops chemical behavioral changes. As a result of this, two main problems emerge. The first problem is that the stability of the products developed is not at a desired level and the shelf life thereof is shortened. Secondly, vildagliptin is reactive against the excipients employed in developing formulations. This fact causes impurities and unwanted components to be included into the formulation.
A further problem encountered while developing formulations comprising vildagliptin is flowability. Problems encountered in the flowability of vildagliptin make its production difficult.
The patent application WOOO/34241 discloses vildagliptin or an acid addition salt thereof, as well as their use in diabetes mellitus and obesity.
The patent application W02006/078593 claims a direct-compression formulation of a DPP-IV inhibitor compound, and preferably of vildagliptin or an acid addition salt thereof.
The patent application W02006/135723 discloses a formulation, comprising vildagliptin as an active agent, as well as hydroxypropyl methylcellulose, microcrystalline cellulose, and magnesium stearate.
There is thus still a need for a formulation that is stable against sensitive of vildagliptin and that provides pharmacotechnical properties such as flowability, compressibility and homogeneity.
Detailed Description of the Invention
The main object of the present invention is to provide a formulation comprising vildagliptin having pharmacotechnical properties such as flowability, compressibility and homogeneity. Another object of the present invention is to provide a formulation comprising vildagliptin having desired stability without side reactions and chemical impurities.
According to one embodiment of the invention, a tablet formulation comprises;
10.0-20.0% by weight of vildagliptin,
- 60.0-85.0% by weight of fillers,
1 .0-10.0% by weight of disintegrants,
1 .0-7.0% by weight of binders,
- 0.1 -3.0 % by weight of lubricants,
0.1 -3.0 % by weight of colloidal silicone dioxide in the formulation wherein tablet is free of coating.
In the present invention, colloidal silicone dioxide is used, so while the formulation comprising vildagliptin is provided pharmacotechnical properties, especially, flowability. Also, certain amounts of excipients are used so while the stable formulation is provided without side reactions and chemical impurities. The formulation has been developed by using standard techniques which is a simple and cost-effective method.
According to one embodiment of the present invention, vildagliptin crystal form “Form A” is used in the tablet formulation. The term “vildagliptin” refers to vildagliptin form A in the present invention.
Suitable fillers are selected from group comprising microcrystalline cellulose, lactose anhydrous, dicalcium phosphate dihydrate, ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, tragacanth, trehalose, polysorbate 80, xylitol or mixtures thereof.
According to one embodiment of the present invention, preferably the amount of the fillers is between 65.0% and 80.0% by weight of the total formulation.
According to one embodiment of the present invention, the filler is microcrystalline cellulose, lactose anhydrous, dicalcium phosphate dihydrate or mixtures thereof.
Suitable disintegrants are selected from group comprising croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, sodium alginate or mixtures thereof. According to one embodiment of the present invention, preferably the amount of the disintegrants is between 3.0% and 7.0% by weight of the total formulation.
According to one embodiment of the present invention, the disintegrants is croscarmellose sodium.
Suitable binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, dextrin, polymethacrylates, pregelatinized starch, sodium alginate, synthetic resins, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, sodium alginate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, polysaccharides, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
According to one embodiment of the present invention, the binder is polyvinylpyrrolidone.
Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium chlorate, magnesium lauryl sulfate, sodium acetate, sodium benzoate, polyethylene glycol, sodium lauryl sulphate or mixtures thereof.
According to this embodiment of the invention, the lubricant is magnesium stearate.
According to one embodiment of the present invention, the tablet formulation further comprising at least one antioxidant.
Suitable antioxidants are selected from the group comprising alpha tocopherol (Vitamin E), quercetine ascorbyl palmitate, ascorbic asit, tartaric asit, cysteine, Lecithin, acetic acid, alpha lipoic acid, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), erythorbic acid, monothioglycerol, potassium metabisulfite, propyl gallate, sodium ascorbate, sodium metabisulfite, sodium sulfite, citric acid, thymol or mixtures thereof. Preferably, antioxidants are selected from quercetine, alpha tocopherol(vitamin E), butylhydroxyanisole or butylhydroxytoluene or mixtures thereof.
According to this embodiment of the invention, the amount of antioxidants is between 0.1% and 3.0% by weight of the total formulation.
As used here in, ‘particle size distribution’ means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. malvern analysis) .The term d(0.1) means, the size at which 10% by volume of the particles are finer and d(0.5) means the size at which 50% by volume of the particles are finer and d (0.9) means the size at which %90 by volume of the particles are finer.
According to this embodiment of the invention, vildagliptin has a d (0.1) particle size between 1 pm to 60 pm, preferably 4 pm to 50 pm, between 4 pm to 40 pm, between 4 pm to 30 pm, between 4 pm to 20 pm, between 6 pm to 18 pm.
According to this embodiment of the invention, vildagliptin has a d (0.5) particle size between 70 pm to 130 pm, preferably 75 pm to 125 pm, between 80 pm to 120 pm, between 85 pm to 115 pm.
According to this embodiment of the invention, vildagliptin has a d (0.9) particle size between 270 pm to 450 pm, preferably 280 pm to 440 pm, between 290 pm to 430 pm, between 300 pm to 420 pm, between 300 pm to 410 pm, between 300 pm to 400 pm.
According to this embodiment of the invention, vildagliptin has a d (0.1) particle size between 1 pm to 60 pm, a d (0.5) particle size between 70 pm to 130 pm, a d (0.9) particle size between 270 pm to 450 pm. This invention provides surprisingly better solubility and also helps to ensure desired pharmacotechnical properties.
The tablet formulation of the present invention may be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, dry granulation, slugging, spray drying.
Furthermore, the sachet formulation is obtained by using a dry granulation method therefore, a simple and low-cost production method was employed.
Example 1 : The tablet formulation comprising vildagliptin
Figure imgf000006_0001
Example 2: The tablet formulation comprising vildagliptin
Figure imgf000007_0001
A process for example 1 or 2; a) Mixing vildagliptin, colloidal silicone dioxide, a part of lactose anhydrous, a part of microcrystalline cellulose, b) Adding croscarmellose sodium, the remained of lactose anhydrous, the remained of microcrystalline cellulose, polyvinylpyrrolidone and then mixing, c) Compacting the mixture with a compactor and then sieving, d) Adding magnesium stearate and mixing, e) Pressing the mixture to form a tablet.
Example 3: The tablet formulation comprising vildagliptin
Figure imgf000007_0002
Example 4: The tablet formulation comprising vildagliptin
Figure imgf000008_0001
A process for example 3 or 4; a) Mixing vildagliptin, colloidal silicone dioxide, a part of lactose anhydrous, a part of dicalcium phosphate dihydrate and at least one antioxidant, b) Adding croscarmellose sodium, the remained of lactose anhydrous, the remained of dicalcium phosphate dihydrate, polyvinylpyrrolidone and then mixing, c) Compacting the mixture with a compactor and then sieving, d) Adding magnesium stearate and mixing, e) Pressing the mixture to form a tablet.

Claims

1 . A tablet formulation comprising
10.0-20.0% by weight of vildagliptin,
- 60.0-85.0% by weight of fillers,
1 .0-10.0% by weight of disintegrants,
1 .0-7.0% by weight of binders,
- 0.1 -3.0 % by weight of lubricants,
0.1 -3.0 % by weight of colloidal silicone dioxide in the formulation wherein tablet is free of coating.
2. The tablet formulation according to claim 1 , wherein vildagliptin crystal form “form A” is used in the formulation.
3. The tablet formulation according to claim 1 , wherein fillers are selected from group comprising microcrystalline cellulose, lactose anhydrous, dicalcium phosphate dihydrate, ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, cellulose acetate, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, tragacanth, trehalose, polysorbate 80, xylitol or mixtures thereof.
4. The tablet formulation according to claim 1 , wherein disintegrants are selected from group comprising croscarmellose sodium, sodium starch glycolate, pregelatinized starch, sodium carboxymethyl cellulose, sodium alginate or mixtures thereof.
5. The tablet formulation according to claim 1 , wherein binders are selected from the group comprising polyvinylpyrrolidone, carboxymethylcellulose sodium, calcium carbonate, calcium phosphate, calcium sulfate, cellulose, dextrin, polymethacrylates, pregelatinized starch, sodium alginate, synthetic resins, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, sodium alginate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, polysaccharides, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
6. The tablet formulation according to claim 1 , wherein lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, calcium stearate, sodium chlorate, magnesium lauryl sulfate, sodium acetate, sodium benzoate, polyethylene glycol, sodium lauryl sulphate or mixtures thereof.
7. The tablet formulation according to claim 1 , further comprising at least one antioxidant.
8. The tablet formulation according to claim 7, wherein antioxidants are selected from the group comprising alpha tocopherol (Vitamin E), quercetine ascorbyl palmitate, ascorbic asit, tartaric asit, cysteine, Lecithin, acetic acid, alpha lipoic acid, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), erythorbic acid, monothioglycerol, potassium metabisulfite, propyl gallate, sodium ascorbate, sodium metabisulfite, sodium sulfite, citric acid, thymol or mixtures thereof. Preferably, antioxidants are selected from quercetine, alpha tocopherol(vitamin E), butylhydroxyanisole or butylhydroxytoluene or mixtures thereof.
9. The tablet formulation according to claim 1 , wherein vildagliptin has a d (0.1) particle size between 1 pm to 60 pm, a d (0.5) particle size between 70 pm to 130 pm, a d (0.9) particle size between 270 pm to 450 pm,
10. The tablet formulation according to claim 1 , comprising vildagliptin, microcrystalline cellulose, croscarmellose sodium, lactose anhydrous, polyvinylpyrrolidone, colloidal silicone dioxide, magnesium stearate.
11. The tablet formulation according to claim 1 , comprising vildagliptin, dicalcium phosphate dihydrate, croscarmellose sodium, lactose anhydrous, at least one antioxidant, polyvinylpyrrolidone, colloidal silicone dioxide, magnesium stearate.
PCT/TR2021/050444 2020-07-06 2021-05-07 A formulation comprising vildagliptin and at least one pharmaceutically acceptable excipient Ceased WO2022010436A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21837553.3A EP4175632A4 (en) 2020-07-06 2021-05-07 FORMULATION COMPRISING VILDAGLIPTIN AND AT LEAST ONE PHARMACEUTICALLY ACCEPTABLE EXCIPIENT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/10700A TR202010700A2 (en) 2020-07-06 2020-07-06 A FORMULATION CONTAINING VILDAGLIPTIN AND AT LEAST ONE PHARMACEUTICALLY ACCEPTABLE EXCLUSIVE
TR2020/10700 2020-07-06

Publications (1)

Publication Number Publication Date
WO2022010436A1 true WO2022010436A1 (en) 2022-01-13

Family

ID=79553558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/050444 Ceased WO2022010436A1 (en) 2020-07-06 2021-05-07 A formulation comprising vildagliptin and at least one pharmaceutically acceptable excipient

Country Status (3)

Country Link
EP (1) EP4175632A4 (en)
TR (1) TR202010700A2 (en)
WO (1) WO2022010436A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078593A2 (en) * 2005-01-18 2006-07-27 Novartis Ag Direct compression formulation and process
WO2015132359A1 (en) * 2014-03-06 2015-09-11 Sanovel Ilac Sanayi Ve Ticaret A.S. Vildagliptin formulation process under inert gas atmosphere

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101106977A (en) * 2005-01-18 2008-01-16 诺瓦提斯公司 Formulation and method of direct compression tablet
GT200600218A (en) * 2005-06-10 2007-03-28 FORMULATION AND PROCESS OF DIRECT COMPRESSION
WO2019219920A1 (en) * 2018-05-18 2019-11-21 Galenicum Health S.L.U Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078593A2 (en) * 2005-01-18 2006-07-27 Novartis Ag Direct compression formulation and process
WO2015132359A1 (en) * 2014-03-06 2015-09-11 Sanovel Ilac Sanayi Ve Ticaret A.S. Vildagliptin formulation process under inert gas atmosphere

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4175632A4 *

Also Published As

Publication number Publication date
EP4175632A4 (en) 2024-08-07
EP4175632A1 (en) 2023-05-10
TR202010700A2 (en) 2022-01-21

Similar Documents

Publication Publication Date Title
EP2938362B1 (en) Dry granulation process for producing tablet compositions of metformin and compositions thereof
EP4112047B1 (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin
EP4410793A1 (en) Solid composition of glp-1 receptor agonist
EP2478909A2 (en) Pharmaceutical compositions comprising bisphosphonate derivatives and high-dose cholecalciferol
BRPI1007237B1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING ALEGLITAZAR
EP4175632A1 (en) A formulation comprising vildagliptin and at least one pharmaceutically acceptable excipient
AU2020413580B2 (en) Complex formulation comprising sitagliptin and dapagliflozin, and preparation method therefor
KR102838282B1 (en) Composite formulation comprising Sitagliptin and Dapagliflozin and a process for the preparation thereof
EP4620522A2 (en) A combination comprising vildagliptin and metformin
EP4497434A1 (en) A film coated tablet formulation comprising empagliflozin
EP1713452B1 (en) Sustained release pharmaceutical composition of indapamide
WO2023234899A1 (en) A bilayer tablet formulation comprising empagliflozin and metformin
EP4008315A1 (en) A process for formulations of dapagliflozin and metformin hydrochloride
EP4008316A1 (en) A film coated tablet formulation comprising dapagliflozin and metformin hydrochloride
WO2021262116A1 (en) A film coated tablet comprising vildagliptin and metformin hci
EP4066820A1 (en) The film coated tablet of vildagliptin and metformin hydrochloride
WO2021020455A1 (en) Vildagliptin-containing dry granulated powder, vildagliptin-containing tablet, and methods for producing these
WO2023107082A1 (en) A film coated tablet of saxagliptin and at least one antioxidant processed with wet granulation
EP4563143A1 (en) A bilayer tablet formulation of metformin and sitagliptin comprising antioxidant
ES2773756A2 (en) Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
TR2023002813A1 (en) A FILM-COATED TABLET CONTAINING SITAGLIPTIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
TR2022003059A2 (en) A PROCESS FOR THE PREPARATION OF A TABLET CONTAINING VILDAGLIPTIN
WO2024005755A1 (en) A tablet comprising empagliflozin
EP4431087A1 (en) A film coated tablet of sitagliptin or a pharmaceutically acceptable salt thereof
WO2021262115A1 (en) A stable combination of vildagliptin and metformin hci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21837553

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021837553

Country of ref document: EP

Effective date: 20230206